Pharma & Biotech Global Week in Review 14 July 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

EU Court of Justice limits scope of patent protection available to gene sequences: Monsanto v. Cefetra (Holman’s Biotech IP Blog) (Patent Baristas) (Patent Docs) (IP Watch) (EPLAW)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

Problem patents in innovative pharma (IP Think Tank)

Patent law changes as eminent domain? Controversial article in Science magazine ‘Fixing the legal framework for pharmaceutical research’ (PatLit)

UN Biodiversity talks resume, last chance for agreement before October deadline (IP Watch)

Battling malaria with open-source weapons? Glaxo tries a ‘Linux’ (Spicy IP)

TB Alliance and DNDi team up to fight neglected diseases (IP Watch)

Australia: Pharmaceuticals extensions and international inequities: H Lundbeck A/S v Alphapharm Pty Ltd, Ortho-McNeil Pharmaceutical, Inc v Lupin Pharmaceuticals, Inc (Patentology)

Australia: The ‘morality’ of gene patents (Patentology)

Belgium: Antwerp commercial court finds Belgian counterpart of EU patent covering process for producing L-Lysine by fermentation valid and infringed: Ajinomoto v. Helm et al. (EPLAW)

EU Court of Justice limits scope of patent protection available to gene sequences: Monsanto v. Cefetra (Holman’s Biotech IP Blog) (Patent Baristas) (Patent Docs) (IP Watch) (EPLAW)

Germany : German parliament members seek limited patent terms in EU-India FTA (IP Watch)

Netherlands: Sufficiency of disclosure finally on the Dutch radar : Novozymes v. DSM (EPLAW)

Netherlands: District Court of The Hague finds 1970 Hansel publication novelty destroying for allergy treatment patent: Alk-Abello v. Stallergenes (EPLAW)

UK: Discovery of documents: is there a real benefit? Abbott Laboratories Ltd v Medinol Ltd (PatLit)

US: Analysis shows patent use codes have doubled since August 2003 (FDA Law Blog)

US: House slips pay-for-delay provision into Appropriations Bill (Patent Docs)

US: Novartis challenges USPTO’s interim procedure for requesting PTA recalculations (Patent Docs)

US: Seven actions related to Enzo’s patents for detecting DNA stayed pending Supreme Court review (Patent Docs)

US: Review and correction of the patent term adjustment calculation: Novartis AG et al. v. Kappos (Patent Docs)

US: Review and correction of the patent term adjustment calculation: Nippon Shinyaku Co., Ltd. v. Kappos (Patent Docs)

Products

Aldara (Imiquimod) – US: Graceway sues FDA over generic Aldara cream decisions; alleges that petition response is contrary to basic science, common sense, and precedent (FDA Law Blog)

Erbitux (Cetuximab) – UK: What is a product? Cetuximab has its day in Court: Yeda Research and Development Company Ltd v Comptroller General of Patents (SPC blog)

Focalin (Dexmethylphenidate) – US: Patent infringement complaint following Paragraph IV certification: Celgene Corp. et al. v. Sun Pharmaceutical Industries, Inc. (Patent Docs)

Lialda (Mesalazine /Mesalamine) – US: Patent infringement complaint following Paragraph IV certification: Shire Development Inc. et al. v. Cadila Healthcare Ltd. et al. (Patent Docs)

Losec (Omeprazole)EU: SPCs and anticompetitive conduct: the General Court speaks: AstraZeneca v Commission (SPC blog) (IP Whiteboard)

Monovisc – US: Patent infringement complaint based on manufacture and sale of Monovisc: Genzyme Corp. v. Anika Therapeutics, Inc. (Patent Docs)

NovoNorm (Repaglinide) – France: Tribunal de Grande Instance: Claims 2 and 3 invalid for lack of novelty: Hexal and Sandoz v. Boehringer Ingelheim Pharma (EPLAW)

Plavix (Clopidogrel) – US: Apotex’s second request for re-examination of Plavix patent denied by USPTO (Patent Docs)

Tarka (Trandolapril, Verapamil) – Sanofi, Abbott successfully request sanctions against Glenmark in Tarka dispute (Patent Docs)

3 Comments on “Pharma & Biotech Global Week in Review 14 July 2010 from IP Think Tank

  1. The denial of reexamination by the USPTO against Plavix patent is yet another way of affirming patentability as the desired dextro rotatory proves more effetive in terms of efficacy and less toxicity. K.M.Senthil Kumar

    Like this

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 20,697 other followers

%d bloggers like this: